83 results about "Ocular surface disease" patented technology

The present invention relates to a method for preparing a contact lens-shaped amniotic dressing and a contact lens-shaped amniotic dressing prepared therefrom for treating ocular surface diseases, which does not require the use of sutures or an adhesion material. The inventive contact lens-shaped amniotic dressing is capable of solving the problems associated with suturing an amniotic membrane, e.g., highly delicate surgical techniques of suturing, long surgery time, stitch abscess, granuloma formation, tissue necrosis, and discomfort of patients; and the problems associated with the use of a support, e.g., the elimination of the support by eye blinking, breaking of the support, and discomfort.

The invention provides apparatuses and methods for detecting ocular surface defects. The methods and/or an apparatus of the invention can be used to detect ocular surface diseases, such as dry eye, uveitis, conjunctivitis, keratitis, keratoconjunctivitis, vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), autoimmune disorders of the ocular surface, meibomianitis, conjunctival hyperemia, eyelid hyperemia, ocular rosacea, ocular inflammation, or eye lid swelling.

Histatins may be used for corneal wound healing and as a treatment for ocular surface disease in humans and other animals. For example, histatins could be included in eye drops, eye gels, ointment, glue, or embedded in (polymer) contact lenses.

A topical eye solution for the treatment of corneal, scleral, or conjunctival diseases. In one embodiment of the present invention, the eye solution comprises a saline-based fluid, and an effective amount of at least one therapeutic compound or agent, wherein when at least one drop of the eye solution is applied to the surface of an eye, the therapeutic compound or agent is released to the cornea and conjunctiva of the eye.

A method of treating an ocular surface disorder in a subject in need of such treatment is provided. The method includes exposing conjunctival tissue of the subject to an effective amount of a vasopermeability agent that increases conjunctival vascular permeability. In some embodiments, the agent is a nitric oxide donor, which may be in a sustained release form. A method of screening a substance for treating an ocular surface disorder is also provided.

Methods of treating humans or animals afflicted with primary blepharospasm, for example, benign essential blepharospasm, or secondary blepharospasm not caused by an ocular surface disease or condition, are component to a human or animal so afflicted.

The invention is directed to topical drug vehicle platform compositions for ophthalmological and dermatological use. These compositions comprise a means to sequester tears and an ophthalmological drug. The invention is further directed to methods of treating a spectrum of ocular surface disease epitheliopathies including but not limited to dry eye in a human or mammal. The invention is further directed to contact lenses, punctum plugs, pellets or any other device used to deliver drugs to the surface of the eye, coated or infused with compositions of the invention.

It is intended to provide a transplantation material applicable to ocular surface diseases with a need for ectocornea transplantation (i.e., an ectocornea-like sheet). Oral mucosal epithelial cells are inoculated onto an amnion and then cultured in the coexistence of supporter cells. When a layered structure of the oral mucosal epithelial cells is formed, the outermost layer is brought into contact with air, thereby inducing differentiation. Thus, an ectocornea-like sheet having an oral mucosal epithelial cell layer on the amnion is obtained.

Described methods and compositions for treating Meibomian Gland Disease (MGD) for normalizing gland secretions and improving symptoms of ocular surface diseases associated with MGD. The methods concern treatment of a patient with aldosterone antagonists, such as spironolactone or analogues of spironolactone. Spironolactone is desirably added in a novel treatment composition, preferably in the form of an aqueous solution, emulsion or suspension in small but effective concentrations and in a novel vehicle that adds to the increased solubility of what previously was known to be an insoluble active agent. Moreover, it is believed that the specific lower but effective concentrations of spironolactone, and/or the pluronic vehicle of the treatment composition, permits optimal expression of essential lipids and upregulation of genes that control lipid production necessary to a more normalized lipid component of the tear film for the treatment and/or the prevention of signs and/or symptoms of MGD.

The invention provides a multifunctional bath patch comprising a soup feed device, a soup input valve, a soup drain valve, a soup input tube, a soup drain tube, a patch frame, a patch nose frame, a patch belt, an inner sealing gasket and a mirror. To treat ocular surface diseases such as ocular surface inflammation, xerophthalmia, dysfunction of eyelid plates, a method of traditional Chinese medicine fumigation on the eyes or iontophoresis are used at present. The multifunctional bath patch is a simple device, a patient can immerse his ocular surface in soup using the patch having functions of a plurality of devices, the principle is like that a facial mask protects the skin of the face, the soup whose temperature is the same as the animal heat can be directly introduced into the ocular surface through the patch to treat diseases such as ocular surface inflammation.

The invention provides Chinese herbal preparation used for curing the allergic conjunctivitis. The Chinese herbal preparation comprises the active ingredients of ephedra, broom cypress fruit, radix sileris, notopterygium root, honeysuckle, densefruit pittany root-bark, hairyvein agrimonia herb and bud, scouring rush, orthostachyus, angelica dahurica, vine of multiflower knotweed, cnidium fruit, polygonum aviculare, euphorbia hirta, paniculate swallowwort root, honeycomb, hypericum sampsonii hance, loranthus parasiticus, talinum crassifolium, centipeda minima, fragrant solomonseal rhizome, liparis nervosa, lindernia ruellioides and liquorice. The Chinese herbal preparation can reduce rate of relapse, can act on ocular surface diseases in relatively long time, maintains curative effect, and reduces side effect.

Disclosed is a common ocular surface disease diagnosis system based on an intelligent terminal. The common ocular surface disease diagnosis system comprises an information acquisition module, a data processing module and a diagnosis and treatment suggestion module, wherein the information acquisition module is installed on the intelligent terminal, and comprises an image acquisition unit, a questionnaire acquisition unit and a basic information acquisition unit; the data processing module is connected with the information acquisition module, and comprises a questionnaire processing module andan intelligent picture classification module, wherein the questionnaire processing module is used for receiving the questionnaire information input by the questionnaire acquisition unit and giving a corresponding ocular surface disease evaluation score; the intelligent picture classification module is used for classifying the input ocular surface pictures by using an ocular surface model stored inthe intelligent picture classification module or in a cloud end, and obtaining classification results of normal ocular surface, viral keratitis, bacterial keratitis, fungal keratitis, pterygium, conjunctivitis and ocular surface tumors; and the diagnosis and treatment suggestion module is connected with the data processing module, receives the evaluation score of the questionnaire processing module and/or the classification result of the intelligent picture classification module, and outputs a corresponding diagnosis and treatment suggestion according to the evaluation score and/or the classification result.

Ophthalmic formulations containing tyrosine kinase inhibitors, such as Nintedanib, Axitinib, Sorafenib, and Pazopanib are described. The ophthalmic formulations can contain microparticles or nanoparticles of the tyrosine kinase inhibitor. Also described are methods of using the ophthalmic formulations for treating ocular surface diseases, such pterygium, including recurrent pterygium, and hyperemia associated with pterygium.

The invention relates to a medical apparatus, and particularly discloses an atomization device used for auxiliary treatment of ocular surface diseases. The atomization device comprises an atomizationdevice body, an atomizer arranged in the atomization device body, an eyeshade, a head wearing device and a heating device, the atomizer comprises an atomization generator and an atomization medicine tank, the eyeshade is integrally connected with the atomization device body, and a nose bridge groove is formed below the portion, making contact with the face of a patient, of the eyeshade; the head wearing device is connected with the atomization device body and adapts to the condition that the atomization device body is worn on heads of different patients, and the eyeshade shades the double eyes; a gas outlet end of the atomization generation device is connected to an atomized liquid spraying port through a tube line, and the atomized liquid spraying port is used for utilizing the eyeshade for seamlessly covering the ocular surface skin and the periorbital skin; the heating device is used for heating gas generated by the atomization generation device to preset temperature. The atomization device used for auxiliary treatment of the ocular surface diseases is simple in structure and convenient to operate and significantly improves the treatment effect.

Compositions, kits, and methods for treating for treating dry eyes in mammal, particularly humans, are described. Such compositions include a pharmaceutically or veterinarily acceptable ocular carrier and a therapeutically effective amount of one or more immune regulatory agents, for example, stimulators and activators of regulatory B or T cells, type 2 immunity-associated immune cells, including group 2 innate lymphoid cells, type 2 CD4+ T helper cells, and alternative activation of macrophages (AAMacs, M2).

The present invention provides an ophthalmic formulation consisting essentially of one or more pharmaceutically acceptable excipients; a pharmaceutically active compound that is capable of reducing the amount of inflammatory neutrophil product on the ocular surface; and optionally a second pharmaceutically active compound selected from the group consisting of a steroid, an anti-inflammatory agent, a mucolytic agent and a combination thereof. In particular, the present invention provides an ophthalmic formulation where the pharmaceutically active compound is capable of treating a clinical condition selected from the group consisting of inflammatory and immunological ocular surface disease that can cause symptoms of ocular discomfort, mucocellular aggregates/debris in tear film, symblepheron formation, fornix foreshortening, eyelid margin/conjunctival keratinization, corneal neovascularization/pannus, subconjunctival fibrosis, and herpetic eye disease. The present invention also provides a method for diagnosing or monitoring an ocular surface disease.